Auris Medical
Cochlear therapies

Innovative Treatments for Inner Ear Disorders

Business Update & Financial Results

Second Quarter 2017

August 10, 2017

Forward-looking Statements

Auris Medical
Cochlear therapies

This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “might,” “approximately,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places throughout this presentation and the accompanying oral commentary and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates AM-101 and AM-111, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These include, but are not limited to, the timing and conduct of clinical trials of our product candidates, the clinical utility of our product candidates, including the likelihood that the TACTT3 trial may not meet its endpoints, the timing or likelihood of regulatory filings and approvals, the timing or likelihood of regulatory filings and approvals, our intellectual property position and our financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to our capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in our Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Addressing the Big Three Neurotology Disorders

Auris Medical
Cochlear therapies

AM-111 — Upcoming Phase 3 HEALOS top-line results

Keyzilen® — Nearing completed enrollment of TACTT3

AM-125 — Preparing to initiate second Phase 1 trial

AM-111: Upcoming Phase 3 Data

- Potential to become first therapeutic indicated specifically for treatment of acute inner ear hearing loss
- Fast track and orphan drug designation
- Product features:
  - Single dose treatment
  - Provides rapid and substantial recovery of hearing
  - Reduces tinnitus associated with hearing loss
- Two Phase 3 trials ongoing:
  - HEALOS: Expect top-line results in 4Q 2017
  - ASSENT: Expect top-line results in 2H 2018

Keyzilen: TACTT3 Phase 3 Trial Ongoing

Auris Medical
Cochlear therapies

- Fast track designation for treatment of acute inner ear tinnitus
- Phase 3 TACTT3 trial:
  - 3Q 2017: Plan to complete enrollment
  - 1Q 2018: Expect top-line results
- Key safety data published in leading peer reviewed journal:

  Staecker H, Morelock M, Kramer T, Chrbolka P, Ahn JH, Meyer T. Safety of repeated-dose intratympanic injections with AM-101 in acute inner ear tinnitus, Otolaryngology-Head and Neck Surgery. 2017:194599817711378.

AM-125: Intranasal Delivery of Betahistine

- Completed transaction with Otifex Therapeutics
- Obtained access to additional relevant preclinical and clinical data
- Assembled data package to support development of intranasal betahistine
- Established Scientific Advisory Board
- Performed modeling studies that delivered further insight into superior bioavailability with intranasal administration route
- Preparing for regulatory discussions
- Plan to initiate second Phase 1 trial in 4Q 2017

Second Quarter 2017 Financial Update

Auris Medical
Cochlear therapies

- **Net loss** decreased from CHF 8.4 million, or CHF 0.25, in the second quarter 2016 to **CHF 5.4 million**, or CHF 0.12, in the second quarter 2017
- **Research and development expenses** decreased from CHF 7.3 million in the second quarter 2016 to **CHF 4.7 million** in the second quarter 2017
- **General and administrative expenses** decreased from CHF 1.7 million in the second quarter 2016 to **CHF 1.2 million** in the second quarter 2017
- **Cash and cash equivalents** as of June 30, 2017, totaled **CHF 26.2 million**
- 2017 **operating expense guidance** remains **CHF 28 to 32 million**

Upcoming Events

AA0-HNSF Annual Meeting & OTO Experience
Hosting scientific symposium:
Targeting Histamine Receptors for Vertigo Therapy
September 11, 2017

LEERINK Partners Rare Disease Roundtable Series
September 27, 2017

Key Upcoming Milestones

Third Quarter 2017	• Complete enrollment of TACTT3
Fourth Quarter 2017	• Announce HEALOS top-line results
Fourth Quarter 2017	• Initiate second AM-125 Phase 1 trial
First Quarter 2018	• Announce TACTT3 top-line results
First Quarter 2018	• Announce AM-125 Phase 1 results



Questions & Answers

Auris Medical
Cochlear therapies



Take care of your ears!

Investor Relations Contact: Cindy McGee
investors@aurismedical.com

Auris Medical Holding AG
Bahnhofstrasse 21
CH-6300 Zug
Tel. +41 41 729 71 94 | Fax +41 61 201 13 51
www.aurismedical.com | NASDAQ: EARS

Auris Medical
Cochlear therapies